drugset / Trial / NCT02171624
Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate
RandomizedCrossoverOpen-labelTreatment
Summary
Open-label, two-way crossover design with a quinidine sulfate run-in period followed by a randomised sequence of dabigatran etexilate plus quinidine sulfate or dabigatran etexilate alone to evaluate the safety of co-administration of dabigatran etexilate and quinidine. and the pharmacokinetic interaction between quinidine and dabigatran etexilate.
Timeline
- Start
- 2009-03
- Primary completion
- 2009-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | — |
| Subject | Quinidine | Small molecule | 200 mg | Oral |
Indications
No indication recorded.